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The characteristics of the national drug policy in India
Introduction to the Indian national drug policy
The current Indian national drug policy has its roots 
in two documents originated in the 70-ties and the 80-
ties of the XX. century. Although the first National Drug 
Policy was declared in 1978, it has been revised thrice 
since then, in 1986, 1994 and 2002 [3]. Also, in 1986 an-
other document on the Indian drug policy, titled “Meas-
ures for Rationalisation, Quality Control and Growth 
of Drugs and Pharmaceutical Industry in India” was 
evolved [1]. The drug policy has been implemented un-
der some legal acts related mainly to the fields of health 
care, family welfare, scientific research and develop-
ment, and industry. It emerged from the findings of the 
Hathi Committee (a committee commissioned to study 
the operations of multinational drug companies vis-à-vis 
indigenous companies and public sector undertakings). 
The committee’s recommendations were released in 
1975 and they included:
1) nationalisation of multinational units,
2) diluting foreign equities of companies coming under 
the Foreign Equity Regulations Act,
3) earmarking some drugs for public sector undertakings,
4) strengthening R&D (research & development) activities,
5) abolishing brand name drugs, 
6) issuing licenses for formulations of only 117 drugs 
which the committee considered sufficient for the 
treatment of the majority of diseases in India,
7) measures for drug quality control,
8) disseminating unbiased drug information to prescrib-
ers and consumers, 
9) monitoring of adverse drug reactions [3].
The national drug policy of India ensures access, 
quality and rational use of drugs [2] and its main objec-
tives are as under [1]:
1) ensuring abundant availability of life saving and pro-
phylactic medicines, at reasonable prices and of good 
quality, 
2) strengthening the system of quality control over drug 
production and promoting the rational use of drugs in 
the country,
3) creating an environment conducive to channelling 
new investment into the pharmaceutical industry to 
encourage cost-effective production with economic 
sizes and to introduce new technologies and new 
drugs, 
4) strengthening the indigenous capability for produc-
tion of drugs.
In 1979 the Drug Prices Control Order was declared, 
which brought 347 drugs under price control [1]. The 
industrial licensing has been made easy and is granted 
keeping in consideration that the basic stage manufacture 
is achieved and undue imports are discouraged. The lat-
ter is achieved through tariff mechanism and EXIM (EX-
port IMport) Policy [1]. However, licensing related to for-
mulations has been abolished except in cases of specific 
cells/tissues targeted formulations [1]. The R&D sector 
has been regarded as thrust areas of exports. In view of 
GATT accord and changes in patent laws, the subject mat-
ter of basic research in drug sector has assumed greater 
importance. The foreign technology agreements are per-
mitted for all the items in the pharmaceutical sector to 
encourage the introduction of newer and more efficient 
technologies [1]. It has to be emphasized that in India the 
pricing issues receive more attention because of the pres-
sure of the industry and the GATT agreement and due 
to the fact that one of the main objectives of the Indian 
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policy is to strengthen the domestic pharmaceutical in-
dustry [5]. Pharmaceutical companies play a significant 
role due to existence of high rate of morbidity and mor-
tality from diseases of deprivation and communicable 
diseases. The responsibility of pharmaceutical sector is 
shared by two ministries, the Department of Chemicals 
and Petrochemicals under the Ministry of Industry and 
the Directorate of Drugs Control under the Ministry of 
Health and Family Welfare [3].
India’s pharmaceutical industry is one of the most 
highly regulated industries in the country. Price controls 
have a strong effect on profitability in the industry [7]. 
Government of India has set up an independent National 
Pharmaceutical Pricing Authority to carry out the price 
fixation for the bulk drugs and the formulations. This 
authority looks into the list of drugs under the price con-
trol and implementation of provisions of Drugs (Prices 
Control) Order. The Government will hold the power of 
review and reclamp the prices of medicines in case of 
unreasonable rise of prices of medicines [1]. 
Today in India about 20.000 firms have licences to 
produce pharmaceuticals. Of these, about 200 units are 
responsible for over 40% of total drug production [3]. 
These are engaged in production of complete range of 
formulations (medicines ready for consumption by pa-
tients) and 350 bulk drugs (chemicals having therapeutic 
value used for the production of formulations) [1]. Good 
Manufacturing Practices (GMP), quality control and 
rational use of drugs are taken care of. Drug Control 
Organisation has been strengthened by establishing sub-
zonal offices. Screening of irrational or harmful drugs 
is an ongoing exercise and 44 categories of formulations 
have been banned so far and the definition of new drugs 
has been widened and guidelines issued on clinical tri-
als. Five leading hospitals at Pondicherry, Chandigarh, 
New Delhi, Bombay and Lucknow have been identified 
as Adverse Drug Reaction Monitoring Centres [1].
Pharmaceutical pricing in India
The Drug Prices Control Order (DPCO) of 1979 di-
vided the drugs brought under the price control into four 
categories according to how essential they were deemed 
to be, allowing maximum profit margins to the least es-
sential drugs. The idea was that the lower profit margins 
from life-saving and essential drugs (Categories I and 
II) would be compensated for by the higher margins for 
Categories III and IV drugs. However, the result was that 
drug companies decreased and even stopped the produc-
tion of life-saving and essential drugs and concentrated 
on the more profitable ones [3]. In India, every year hun-
dreds of people still die from malaria for which chlo-
roquine is a cheap but effective remedy; thousands go 
blind due to lack of vitamin A, and millions suffer from 
endemic goitre due to iodine deficiency. India has also 
the largest number of people suffering from tuberculosis 
and leprosy in the world. The 1987 Drug Prices Control 
Order reduced the number of price controlled drugs from 
347 to 142 and increased the maximum profit margins for 
these drugs. Moreover, the 1995 DPCO also decreased 
the number of some drugs essential for public health, 
like ferrous sulphate for anaemia and most of drugs for 
tuberculosis, malaria, leprosy, rheumatic heart disease, 
rabies vaccine, cancer and tetanus [3]. This resulted in 
decrease of the number of essential drugs reaching the 
poor. Moreover, Indian markets are flooded with over 
100,000 formulations and there is no system of central 
registration of these formulations. These drugs are sold 
under numerous brand names rather than their generic 
names, resulting in phenomenal increase in drug prices 
[3]. Although the ceiling prices are fixed for the drugs 
for commonly marketed standard sizes of price-control-
led formulations [1], the pharmaceutical policy of 2002 
calls for further relaxation of production and price con-
trols. It is expected that less than 40 drugs will remain 
under price control [3]. So, while in 1979 there were 347 
drugs under price control, in 2004 the number dropped 
to 74. This has resulted in exorbitant price rises [4]. In 
India it was noted that the increase in the price of the 
basket of drugs was linked to the New Drug Price Con-
trol Order and that the quality of the drugs in the basket 
was comparatively poorer than the quality of drugs in 
general. This seems to reflect a shift in the practice of 
the industry, the essential drugs under generic name be-
ing left for production to small manufacturers, most of 
which did not enforce the GMP (Good Manufacturing 
Practices) [5].
Pharmaceutical supply systems and quality assurance in India
Since 1983, the government has issued various orders 
banning several harmful and/or useless formulations 
marketed in India, but to little effect [3]. Despite the phe-
nomenal growth of the drug industry during the past five 
decades, the availability of modern drugs is still low. For 
example, in 1984 only 5% to 6% of the population could 
afford the modern drugs they needed. Another 25% had 
limited access to essential drugs [3]. Moreover, a majority 
of people living in rural areas and urban slums, the main 
victims of endemic and epidemic diseases, had little or 
no access to modern drugs. The market structure of the 
Indian pharmaceutical industry is skewed with a small 
number of large firms and many smaller pharmaceutical 
companies. The large private sector includes domestic 
manufacturers, foreign controlled companies (with more 
than 25% equity held by a foreign company) and smaller 
private firms. Therefore, pharmaceutical policy in India 
is perceived as industrial policy, not a health policy [7].
Most of the Indian drug manufacturers are privatel-
owned, small-scale and many of them use problematic 
quality assurance systems and procedures. On the other 
hand, due to strict regulations, some of the Indian manu-
facturers have proven their ability to take a product from 
API (active pharmaceutical ingredient) to finished dose 
form at a level of quality suitable for use in regulated 
markets [7]. The quality of drugs, mainly in the pri-
vate sector, remains an important problem in India [5]. 
There is a considerable variability in the quality of drugs 
throughout the country. About one in 10 of all private 
pharmacies reported quality violations, with most of the 
tom VI, nr 1–2/2008 45
leki za granicą
“out of quality” drugs being manufactured by smaller 
firms. Each Indian state is responsible for quality assur-
ance activities and there is wide variation in implemen-
tation [7].
Rational use of drugs in India
In the absence of a clear, comprehensive and rational 
drug policy, a distorted pattern of drug production and 
the proliferation of non-essential, irrational and harmful 
drugs can be still observed in India. The All India Drug 
Action Network (AIDAN) is a network of civil society 
organisations, that has been campaigning for a rational 
drug policy for the last two decades [3]. The government 
has taken little initiative to fulfill its statutory function 
to monitor manufacturers’ promotional literature and 
has taken no steps to supply objective and unbiased drug 
information to prescribers. Some constituent bodies pub-
lish drug information bulletins for prescribers. However, 
representatives of pharmaceutical companies are the 
only source of information to prescribers in remote ar-
eas [3]. The picture in terms of accessibility to essential 
drugs is not impressive.
Pharmaceutical research in India
Accordingly to the TRIPS (Trade-Related Aspects 
of the Intellectual Property rights) compliance of 2005, 
Indian pharmaceutical companies now have to patent 
pharmaceutical products. This will likely provide access 
to international technology, R&D and global marketing 
but its may also result in rising drug prices and intra-
country competition from the many indigenous drug 
companies. Indian pharmaceutical companies will have 
to develop their own “know-how” and R&D centers to 
cope with what will be fierce global competition within 
and outside the Indian market for branded medicines. As 
companies like Ranbaxy Laboratories and Dr. Reddy’s 
Laboratories are pushing to expand their exports and are 
increasing their spending on R&D with hopes of becom-
ing more important players worldwide, the traditional 
business models for Indian drug makers will not work 
much longer. The responsibility to stimulate R&D and 
promote local industry is most often discussed in terms 
of industrial, rather than health, policy. This seems to be 
also the approach by the International Finance Corpora-
tion (IFC). Most of the pharmaceutical industry projects 
supported by the IFC focus on exports rather than seek-
ing to satisfy internal health needs or address affordabil-
ity problems [7].
Final remarks on Indian drug policy
India is well on its way to becoming a global “in-
novation-intensive pharmaceutical giant”, helped by the 
fact that policy makers and the government are planning 
to increase national spending on pharmaceuticals R&D 
[6]. The following problems have been recently highlited 
with regard to the future of the Indian drug policy:
1) the need to review the hypotheses on policy process,
2) the identification of specific policy innovations from 
the cross-national approach that could improve the de-
sign and the implementation of pharmaceutical policy,
3) the ways to improve the political feasibility of imple-
menting those innovations within specific political 
contexts [5].
Drug and health activist organisations have recently 
intervened in a petition challenging the government’s 
recent move to further curtail the number of drugs under 
price control. At the heart of these efforts is the principle 
of entitlement. Neither the Constitution nor the National 
Health Policy guarantees the right to health or to medi-
cal care including affordable and appropriate drugs. The 
community of health professionals must recognise this 
right and help people exercise it [3].
The ensuring the effective implementation of a policy 
requires continuous tending, caring, revising and weed-
ing, much like a garden. Lack of attention during the 
phase of implementation can result in a policy falling 
into disrepair or even reversal. In many ways, the most 
difficult challenges occur during implementation, when 
the goals and mechanisms of a policy must be put into 
practice [5].
The characteristics of the national drug policy in Nepal
Objectives and major components of the national drug policy of Nepal
Nepal is a landlocked country in the South East Asia 
Region with its borders as China and India. It is one of 
the low income countries in the region and harbours 
a population of about 27 million. The government of 
Nepal has formulated the National Drug Policy in 1995, 
in consistency with the National Health Policy of 1991. 
This policy has been designed in order to ensure the ac-
cess, quality and rational use of the drugs in the country. 
The main objective of the National Drug Policy is “To 
maintain, safeguard and promote the health of people 
by making the country self-reliant in drug production; 
ensuring the availability of safe, effective, standard, and 
quality drugs at affordable price in quantities sufficient 
to cover the need of every corner of the country; and to 
manage effectively all the drugs-related activities includ-
ing production, import, export, storage, sale, supply and 
distribution” [8]. The other objectives include the estab-
lishment and promotion of the national pharmaceutical 
companies’ production capacity thereby promoting the 
domestic drugs. It also focuses on development of hu-
man resources for the pharmaceutical sector along with 
establishing the quality control lab for the testing, ana-
lyzing and standardization of drugs. The policy also has 
the objective of monitoring the uniformity of the drug 
prices and promotion of the Ayurvedic, homeopathic and 
other forms of traditional medicine.
Several policy strategies have been developed and 
implemented to achieve the objective set by the National 
Drug Policy. The strategies are basically developed as 
per the WHO’s guideline and they cover all the basic 
components needed in a National Drug Policy. These 
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strategies for the improvement of drug use are broadly 
educational, managerial, economic and regulatory.
Selection of essential drugs and ensuring a proper 
supply system is one of the components. The policy aims 
to develop a list of essential drugs to be used at different 
levels of health facilities in the country, in accordance 
with the WHO’s concept of essential drugs. For proper 
supply system the procurement, storage and distribution 
strategies are formulated. The procurement is supposed 
to be done by opening tenders and from authorized phar-
maceutical companies identified by the Government of 
Nepal. The procurement should be done as per the ge-
neric names of the drugs. The procurement, storage and 
distribution of drugs should be carried out by qualified 
pharmacy personnel. For the sustainability of the supply, 
of the required drug volume, the strategy of partial and 
full cost sharing has been adopted and will be expanded 
in a phase wise manner throughout the country. The 
policy has also provided the room for the introduction 
of modern and scientific methods for the proper supply 
and distribution of drugs and for necessary changes for 
the betterment.
Regulation and quality assurance is another com-
ponent required in a National Drug Policy. The drugs 
quality should be monitored regularly. The National 
Drug Policy of Nepal mentions the development of Na-
tional Medicines Laboratory as an independent national 
quality control lab and phase wise extension of the five 
regional drug testing labs throughout the country. The 
policy mentions that the drug registration in Nepal will 
be based on the scientific facts and standards. The drugs 
not meeting the given standards will be banned. The cer-
tificate of the “Good Manufacturing Practices (GMP)” 
as per the WHO is compulsory for the registration of im-
ported drugs, while the standards of “The National Code 
of Drug Manufacturing Conduct” are to be followed by 
the manufacturers of domestic drugs. The drug regis-
tration is supposed to be updated regularly and for the 
imports of drugs a specific custom point has been set. 
Rational use and education is another major compo-
nent of the National Drug Policy of Nepal. The provision 
for the regular training of the health workers prescribing 
drugs in various levels of health facilities on “Standard 
Drug Treatment Schedule” exists and the health workers 
should follow the schedule of their level while prescrib-
ing drugs. This promotes the rational use of drugs. It has 
been mentioned that for the promotion of the rational use 
of drugs necessary training modules and guidelines will 
be developed and pharmacists and other health personnel 
at hospitals will be trained on the production technology, 
quality assurance and GMP. “Drug Information System” 
for providing the information details on drugs is to be 
developed in an effective manner. The involvement of 
the private sector in providing information on drugs 
and their rational use is also necessary. The National 
Antibiotic Control Committee is the body responsible 
for the prudent use of the antibiotics, while the National 
Antibiotics Therapeutics Advisory Committee provides 
necessary advice on different antibiotics.
Human resource development and promotion of 
national drug companies, as a component in the Na-
tional Drug Policy, relates to the development of phar-
macy personnel from the academic and non-academic 
institutions and it puts the domestic pharmaceutical com-
panies, domestic drugs and importation of the needed 
pharmaceutical machineries into the national priorities. 
Promotion of traditional medicines is another 
unique component. There are various plans set up for 
the promotion of the traditional medicines such as the 
Ayurvedic medicines and homeopathic medicines in 
Nepal. Some of them are: development of needed human 
resources; development of formulary on dosages; scien-
tific evaluation of safety, efficiency and efficacy. 
Regular research and development has been 
planned. Regular randomized clinical trials of new 
drugs are supposed to be performed by the Nepal Health 
Research Council under the Ministry of Population and 
Health. Researches on new technologies are planned to 
be conducted regularly.
Monitoring and evaluation and seeking technical 
cooperation is also an essential component of the Nation-
al Drug Policy of Nepal. Plans for the regular monitoring 
of the policy implementation are mentioned, as well as 
that with co-operation of national and international or-
ganization, training and technology exchange activities 
in the pharmaceutical sector will be conducted.
Implementation of the national drug policy in Nepal
The National Drug Policy of Nepal has been devel-
oped as per the WHO guidelines. Accordingly to the 
WHO it is recommended to all the countries to formulate 
and implement a comprehensive national drug policy. As 
a rule, the national drug policy should show the evidence 
of commitment for achieving the desired goals and pro-
vide guidance to reach the goals. The broad objective of 
the national drug policy is to promote equity and sustain-
ability of the pharmaceutical sector. Other basic objec-
tives are to ensure the access, quality and rational use of 
drugs. A national drug policy should fit with the country 
situation, national health policies and political priorities. 
It should fit within the framework of a national health 
policy and a particular health system and it should be 
consistent with broader health objectives [9].
The comprehensiveness is the strength of the Na-
tional Drug Policy of Nepal. It has been developed in 
consistency with the National Health Policy and it has 
covered the three major areas of access, quality and ra-
tional use. The approaches are developed and refined 
within the national political context. The guidelines and 
appropriate checklists are properly developed. Some of 
the examples are:
1) the guidelines for drug donation,
2) the guidelines for the ethical promotion of medicines 
(this includes several rules to be followed by phar-
maceutical companies while promoting their drugs, 
such as sample medicine provision, sponsoring health 
workers or programs, etc.),
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3) the guidelines on labelling or stability of pharmaceu-
tical products.
The lists of drugs banned in Nepal also exists and the 
list of psychotropic and narcotic substances is updated. 
The record keeping of administered psychotropic and 
narcotic drugs is a mandatory practice. Other impor-
tant points of the National Drug Policy are the several 
criterions to be fulfilled within the process of the new 
company registration, which are designed to prohibit the 
entry of poor quality companies. There are some special 
forms developed by the Department of Drug Admini-
stration to monitor the quality and safety of drug use in 
the country. Examples of them are: the Adverse Drug 
Reaction Form, the Sample Submission Form and the 
Auditors Notebook for GMP [10].
Not surprisingly, what happens in most of the coun-
tries, the implementation of the policy is not fully wor-
king as expected. Though the National Drug Policy is in 
place, the question: “Does it function properly?” needs 
to be answered, as most often the policies might limit 
themselves to the paper itself.
The rules set by the drug policy in Nepal are not 
found to be implemented fully. There exists the lack of 
concerns for financing and pricing issues. The prices of 
drugs are not found consistent all over the country and 
the difficult topographical features of the country wor-
sen this situation further. The difference in performance 
due to the geographical situation of the country has not 
been addressed by the National Drug Policy. It is always 
difficult to supply the drugs in the remote areas, for the 
hard to reach populations. Also a standard storage system 
might not be available which will lower the shelf life of 
the drugs. Though effort has been made to prepare the 
list of essential drugs to promote the rational use in every 
level of the government health facilities, least attention 
has been paid towards the private sector. The private he-
alth facilities and clinics are not obliged to follow the es-
sential drug lists used in the government health facilities 
and this might result in the irrational drug use. There is 
a need to address this issue in the National Drug Policy.
Another example of poor implementation of the Na-
tional Drug policy of Nepal is the weak regulation of 
the drugs which can be sold without prescription (OTC 
drugs). The OTC drugs usage is often likely to be ir-
rational in Nepal. Also, the pharmacies generally do 
not have the appropriately trained and qualified human 
resources. Though it has been mentioned in the policy 
that the different clinical trials will be carried out for 
introduction of new drugs, nothing much has been done 
in this sector. 
Conclusions on the national drug policy of Nepal
National Drug Policy of Nepal is very much consi-
stent with the National Health Plan and envisages the 
concept of equitable access, good quality and rational 
use. It incorporates basically four major strategies, i.e. 
educational, managerial, economic and regulatory – for 
achieving the objectives set forth. As Nepal follows 
a competitive market system, where both domestic and 
foreign manufacturers compete, the implementation of 
the policy should be strengthened further. Focus has to 
be given in enforcing the regulatory measures and pro-
duction of the necessary human resources to carry out 
tasks as reflected by the policy. The affordability and 
price uniformity of the drugs should also be taken as 
point of high priority, as about one third of the country 
population lives below the national poverty line and this 
population might not be able to access the drugs it needs. 
There is much to be done in the area of increasing com-
munity awareness of effects, risks and benefits resulting 
from the use of drugs and also in the area of promoting 
the rational drug use. The quality control labs need to be 
extended so that quality checks can be done regularly. 
Thus, the Department of Drug Administration under the 
Ministry of Health and Population of Nepal, as well as 
other key stakeholders, such as pharmaceutical compa-
nies, health workers and consumers, should all play an 
effective role in implementation of the National Drug 
Policy. Only this way the objectives set by the National 
Drug Policy would be met, contributing to the improve-
ment of health status of the population.
The characteristics of the national drug policy in 
Bangladesh and its role in development of the national 
pharmaceutical industry
Introduction to the pharmaceutical policy of Bangladesh
In most of the low income countries where out-of-po-
cket expenditure is the major source of health care finan-
cing, pharmaceutical expenditure usually is the largest 
part of the healthcare expenditure. Moreover, in both de-
veloped and developing countries, recent pharmaceutical 
inventions and innovations are some of the main reasons 
for global increase of healthcare costs [11]. Bangladesh 
is one of these low income countries in South East Asia, 
having more than 80% of its healthcare expenditure 
spent out-of-pocket [12]. The total healthcare system is 
fairly inadequate to provide even minimal coverage to 
the population. The current GDP of the country is 488 
USD per capita and state is investing only 3% of its GDP 
to the healthcare sector [12, 13]. Only 28.4% of the total 
healthcare expenditure is contributed by the state and 
whole remaining part is paid out-of-pocket [12]. Almost 
80% of the out-of-pocket expenditure is spent on phar-
maceutical products. Because of their high prices, the 
pharmaceutical products are often not accessible to the 
ordinary people. As a result, the complete cycle of treat-
ment is quite a rare experience for the poor people.
Bangladesh has had the pharmaceutical policy in-
troduced in 1982 under a military regime. The existing 
drug policy is quite old and insufficient to meet the cur-
rent challenges, faced by the pharmaceutical sector as 
well as the whole national healthcare sector. Although 
a preparation of a new drug policy has been finalized 
in 2004, at the official level, this document is yet to be 
passed by the national parliament. Official version of the 
latest drug policy is not yet available publicly. 
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The aim of this chapter is to describe the characteri-
stics of the pharmaceutical policy of Bangladesh and to 
explain the role of this policy in development and regu-
lation of the national drug industry and practices related 
to drug use and management. This chapter also covers 
these issues of pharmaceutical policy that are related 
to ensuring the adequate access to the necessary drugs 
for all citizens of the country. The overall discussion is 
based on the drug ordinance of 1982 as the latest drug 
policy is still not accessible [14].
Healthcare system of Bangladesh in brief 
Due to very low investment of GDP on health, the 
overall healthcare status in Bangladesh is not good. 
Bangladesh achieved a significant improvement in va-
rious health care indicators in recent years but overall 
healthcare system is still in a primitive condition. The 
majority of the disease burden is due to the nutritional 
disorders of children and various infectious diseases but 
also there is a growing trend of incidence of non-infec-
tious diseases, like cardiovascular ones and diabetes. 
There are two basic types of healthcare sub-systems in 
Bangladesh – public and private. Within the private he-
althcare system there are organizations which are private 
for-profit and not-for-profit. In public hospitals patients 
are supposed to get services almost free of cost, except 
a very minimum user fee, but in reality the public hospi-
tals are lacking many resources, like diagnostic services 
or medicines. It is almost given that only prescription 
is possible to be received in a public hospital instead of 
the drugs. It means that patients have to buy necessary 
drugs and medical supplies. The Ministry of Health and 
Family Welfare, as the department of the government 
which is responsible for looking after the whole health-
care system, has three major wings. They include three 
directorate offices covering health, family planning and 
affairs related to drugs and diagnostics. The directorate 
of drug administration is the highest regulatory authori-
ty for the pharmaceutical sector in Bangladesh. The mis-
sion of this organization is to ensure that the common 
people have an easy access to the useful, effective, safe 
and good quality essential drugs and also other drugs, 
at affordable prices. Currently there are three streams 
of drug producers in Bangladesh: Allopathic, Homeopa-
thic, Unani and Ayurvedic. There is a total of 807 drug 
manufacturers, including 231 Allopathic, 204 Ayurvedic, 
295 Unani and 77 Homeopathic drug producers [14].
Evolution of drug policy in Bangladesh
The basic drug policy was introduced in unified In-
dia in 1940 by the colonial British administrations. As it 
was introduced by the British government, the inherent 
intention and most of the clauses of the drug policy were 
actually in favor of expanding British market in this sub-
continent. Bangladesh was a part of Pakistan after gai-
ning independence of India from British colonial regime 
and further in 1971 Bangladesh became an independent 
country. Unfortunately Bangladesh had no drug policy 
until May 1982. With some amendments, Bangladesh 
was following that primitive drug policy developed by 
British administration. 
Before introduction of the Drug (Control) Ordinance 
of 1982, the drug regulations were being very weakly en-
forced. Before the Drug Ordinance of 1982, there were in 
total 4,170 brands of drugs which were produced by the 
modern pharmaceutical companies under the regulations 
of the Drug Act of 1940. As part of the existing industry 
did much progress by that time and also the medical pro-
fessionals had progressed at a significant pace, the drug 
Act of 1940 was considered grossly out-dated and inade-
quate to meet the needs of healthcare system. It was espe-
cially inadequate for controlling the prices of pharma-
ceutical raw materials and processed drugs. As the drug 
policy was not updated properly, it also failed to prevent 
the appearance of substandard and spurious drugs on the 
market. There were also present problems of unethical 
promotion performed by pharmaceutical companies and 
proliferation of harmful and useless drugs. Surprisingly, 
it was found that most of the drugs on the market were 
useless, unnecessary and even harmful in some cases. 
From 166 licensed pharmaceutical companies only eight 
multinational pharmaceutical companies produced 75% 
of the total supply of drugs. The drug manufacturers did 
not bother to ensure supplies of essential and life saving 
drugs to the common people of Bangladesh, one of the 
least developed and poorest countries in the world. Many 
pharmaceutical companies were involved in production 
of unnecessary and marginally useful drugs of doubtful 
value, such as vitamins, tonics, enzymes, alkalisers, gri-
pe waters, cough mixtures, etc. To stop the production of 
these useless, unnecessary or harmful drugs, to control 
the import of drugs, to ensure the basic health needs of 
the poor and vulnerable people, to stop the misuse and 
dispatch of foreign currency, an eight member expert 
committee was formed on 27 April 1982. According to 
its recommendations, the National Drug Policy (NDP) 
was promulgated on 12 June 1982. For many reasons the 
previous drug policy was inefficient to meet the country’s 
needs. There were identified at least five prominent cau-
ses to replace the former drug policy by a newer one:
1) problems related to the price control,
2) huge number of unnecessary drugs on the market,
3) presence of outdated and harmful drugs,
4) absolute dependency of the country on the multi-na-
tional pharmaceuticals companies,
5) lack of initiatives to grow local industries.
To combat these problems and to develop a strong 
local industry, first drug policy was introduced by a mi-
litary government in June 1982. In reality, it was not 
a well developed drug policy with a proper vision but 
nevertheless it had some positive impact. Initially there 
were 13 objectives and 16 regulatory clauses in the policy 
document and later on additional eight objectives were 
included. The basic idea of the drug policy was to ensu-
re the access to the essential medicines, to the general 
population at reasonable prices and to develop a strong 
and modern local pharmaceutical industry sector. The 
objectives in the policy document were as follows: 
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 1) to ensure the availability of essential drugs at reaso-
nable prices,
 2) to control the prices of imported drugs,
 3) to gradually stop the imported and locally manufac-
tured unnecessary drugs, 
 4) to promote local industry set up to attain the essen-
tial drugs production,
 5) to prohibit importing and manufacturing of injurio-
us drugs,
 6) to abolish unethical advertisement and promotion of 
drugs,
 7) to control prices of raw materials,
 8) to ensure that all companies, including multinational 
ones, will obligatorily produce the essential drugs,
 9) to establish the drug courts,
10) to ensure legal punishment for any violation of the 
drug rules or in case of adulteration of the pharma-
ceutical products, 
11) to strengthen the system of procurement, storage 
and distribution of drugs, 
12) to give the priority to provide legal and financial 
coverage for the industrial establishment by local 
initiatives,
13) to take gradual steps to produce and sell all medicines 
under their generic names instead of the trade names.
There were 16 additional clauses as drug rules or 
criteria to be maintained by pharmaceutical companies 
in the country. These 16 criteria were mostly related to 
the production and promotional practices. For example, 
all kinds of fixed dose combination (FDC) preparations 
were banned as these combinations were not properly 
graded and might cause toxic effects to the patients. 
All kinds of narcotic drugs were extremely restricted 
in use and only the pharmaceutical companies, which 
were owned by the country government, were allowed 
to produce them. Some substances were also banned to 
be used in any preparations, for example the codeine 
or its derivatives were on such a negative list. To make 
the drug policy more uniform to all sectors, some im-
portant recommendations were adopted, including the 
selection of essential drugs and their classification, the 
preparation and publishing of the national formulary, the 
development of an independent registration system for 
the Ayurvedic, Unani and Homeopathy medicines or the 
establishment of one national and a few regional drug 
testing laboratories.
After the introduction of the drug policy there was 
a serious enforcement of the regulatory rules in the ini-
tial few years. This enforcement resulted in emergence 
of the new era in the pharmaceutical sector development. 
The total number of registered products, both locally 
produced and imported, was 4,340. Out of a total of abo-
ut 4,000 brands of allopathic drugs in the market, the 
Drug (Control) Ordinance cancelled the registration or 
license of 1,742 brands manufactured or imported into 
Bangladesh. These drugs were considered as unnecessa-
ry or even injurious ones. Out of these 1,125 were locally 
produced drugs and 617 were imported drugs. Several 
companies registrations were cancelled or suspended 
for not maintaining the due quality and the appropria-
te production practices. During that period, altogether 
212 pharmaceutical companies were in the sector; 
48 companies were suspended and nine companies were 
totally liquidated. Even multinational companies were 
also facing problems with compliance to the new regula-
tions and some of them had to leave their operations due 
to the lessened profitability. Small drug retailers were 
also under the monitoring umbrella of the drug policy, 
because one of the objectives of the drug policy was to 
develop the drug retailers chains owned by the trained 
pharmacists.
The pharmaceutical policy impact  on the drug industry in Bangladesh
One of the most remarkable aspects of the develop-
ment of the pharmaceutical industry in Bangladesh is 
the emergence of local companies in wake of the Drug 
Control Ordinance of 1982. The policy provided ad-
ditional legislative power to control this sector and to 
provide appropriate legal coverage. The Drug Ordinan-
ce of 1982 had played the supreme role in development 
of the national pharmaceutical market and the national 
pharmaceutical industry. In reality this drug policy ulti-
mately “reversed the pyramid”. Before 1982 there were 
212 pharmaceutical companies in the country and out 
of them only eight Multi National Companies (MNC-s) 
were producing 75% of the total market production. The 
remaining 204 companies produced only 15% of the 
market share [15]. After two decades the total picture has 
been changed to show reversed proportions: in the recent 
yearly statistics the number of pharmaceutical compa-
nies is almost the same, with a marginal increase (231), 
but currently the local companies produce almost 95% 
of the market share and the remaining part is produced 
by MNC-s. Earlier Bangladesh had to import pharma-
ceutical products made by 122 foreign companies from 
23 different countries. Now the Bangladeshi local phar-
maceutical companies export their drugs to 52 different 
countries, including the USA, the UK and many other 
developed and developing countries [14]. The market 
volume increased several hundred folds. Currently the 
pharmaceutical market size is almost 537 million Taka 
per quarter, that means almost 500% growth from the 
pre – drug policy time. After establishing the national 
drug testing institute, the rate of testing newer drugs has 
increased and at the same time the rate of using the sub-
standard drugs has also decreased significantly. 
Constraints and challenges  of the national drug policy of Bangladesh
The prominent limitation of the current drug policy is 
that it is more than two decades old and it urgently needs 
to be updated. During these two decades both national 
and international perspectives of the healthcare system 
have changed a lot. The number of essential drugs has 
been raised enormously and these new drugs should be 
included into the Bangladeshi essential drugs list as soon 
as possible. Also the prices of the locally made generics 
and the innovative molecules should be reviewed to bro-
aden accessibility for the poor people. The WHO and 
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some other international organizations have developed 
specific features of drug policy for the low income co-
untries and they should be reviewed and incorporated. 
The pharmaceutical marketing expenditures are rising 
and that leads to the increases of drug prices in the local 
market [16].
The number of companies producing traditional 
medicines is quite high but still the market shares of 
these companies are not high. As a low-income country, 
Bangladesh is enjoying some extra benefits and exemp-
tions from TRIPS and other international business agre-
ements. According to the TRIPS agreement, Bangladesh 
will be able to produce many innovative drugs from 
2016. However, Bangladesh has no backup industries 
involved in making raw materials and necessary machi-
neries, therefore the country may not be able to grab this 
opportunity. The current drug policy is not suitable to 
support the development of these kinds of backup in-
dustries and to facilitate the further development of the 
local pharmaceutical industry. 
To ensure more accessibility to the essential drugs 
for the poor people of the country, the list of the essential 
drugs should be updated immediately. The price controls 
should be adopted not only in relation to the essential 
drugs but also to some special drugs, e.g. the oncological 
ones.
The Drug Ordinance of 1982 has created quite favo-
rable conditions both for the Bangladeshi patients and 
the local industry. It is expected that the forthcoming 
drug policy will reflect the international recommen-
dations of essential drugs and at the same time it will 
be still or even more favorable for developing the local 
pharmaceutical industry along with the establishment of 
the supportive industrial sector.
The concluding remarks on features of the national 
drug policies of India, Nepal and Bangladesh
The three countries of the Indian sub-continent have 
undergone significant changes in the recent decades. In-
dia has become a pharmaceutical giant producing drugs 
which are exported not only to other countries in the 
Asian region but also to many developing and developed 
countries worldwide. The adherence to the GMP standar-
ds or maintaining the appropriate quality in the proces-
ses of drug production are no longer problems for many 
Indian companies and they promote their successful per-
formance on the international drug market. Neighboring 
Nepal focuses mainly on its internal market and makes 
efforts to accommodate to the challenges brought by ad-
vances in the area of modern health care. Bangladesh is 
making efforts to provide equitable and affordable but 
basic health care coverage for the poor majority of its 
population and has some successes in this task.
The pharmaceutical policies in all of these three co-
untries have important places as the very specific parts 
of the broader national health policies. To some extent all 
of these drug policies are lead by the guidelines establis-
hed by the WHO for national drug policies worldwide. It 
seems that Bangladesh should make the biggest efforts 
in order to up-date its drug policy and to fit better into 
the changing landscape of contemporary health care and 
global economy of the XXI. century. Still struggling to 
provide the most basic help for its poorest citizens, Ban-
gladesh in its own way is bravely entering markets of the 
richest countries of the world, offering them its home 
produced pharmaceuticals. Bangladesh is also thinking 
about reaching the full compliance with the internatio-
nal agreements on the intellectual property rights – so-
mething too difficult to imagine some time ago. Nepal 
has quite well organized and planned pharmaceutical 
services and this country is probably just in the eve of 
reformulating its drug policy originated more than a de-
cade ago.
Interestingly to the countries of the West, the role of 
the traditional medicines, like Ayurvedic or homeopat-
hic ones, is not decreasing on the Indian sub-continent. 
To the contrary, they all have their important places in 
the official drug policies and in some way they are even 
prioritized and their use is unchangeably popular within 
the wide populations.
Streszczenie:
Charakterystyka współczesnych polityk lekowych Indii, 
Nepalu i Bangladeszu
Słowa kluczowe: polityka lekowa, przemysł farmaceutyczny, 
dostępność leków, reformy opieki zdrowotnej, Bangladesz, Indie, 
Nepal
Artykuł charakteryzuje polityki lekowe trzech krajów subkontynentu in-
dyjskiego: Indii, Nepalu i Bangladeszu. Wszystkie spośród tych polityk 
mają swoje głębokie źródła w czasach kolonialnych, gdy ta część świata 
znajdowała się pod panowaniem brytyjskim, oraz odnoszą się do złożo-
nej problematyki azjatyckich krajów rozwijających się. Indie kładą coraz 
większy nacisk na innowacyjność i stają się „globalnym gigantem far-
maceutycznym”, prowadzącym ekspansję nawet na rynki krajów bardziej 
od siebie rozwiniętych. Wysiłki Nepalu skupiają się przede wszystkim 
wokół problematyki wewnętrznej; kraj ten podejmuje wyzwania związane 
z unowocześnieniem opieki zdrowotnej. W Bangladeszu kładziony jest 
nacisk na to, aby w sposób sprawiedliwy i przystępny zapewnić podsta-
wowe świadczenia zdrowotne dla bardzo biednej większości swojej po-
pulacji. Na całym subkontynencie indyjskim mają bardzo duże znacze-
nie leki wywodzące się z medycyny tradycyjnej, w tym takich jej gałęzi, 
jak Ayurveda lub znacznie młodsza homeopatia. Wymienione charakte-
rystyki mają swoje odzwierciedlenie w krajowych politykach lekowych. 
Wszystkie trzy kraje omawiane w artykule znajdują się na różnych eta-
pach zaawansowania we wdrażaniu ochrony praw własności intelektu-
alnej, która odnosi się również do leków. Do pilnych i priorytetowych 
zadań polityk zdrowotnych a także lekowych tych krajów należy wciąż 
zapewnienie obywatelom dostępu do leków podstawowych, określanych 
przez WHO jako essential drugs.
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